Researchers used cells taken from 71 patients with colon and rectal cancer and grew miniature 3-D tumors that were specific to each person.
What they did: Scientists tested 55 different drugs—some currently available and others experimental—on all the mini-tumors (also known as “organoids”).
The findings: The technique was better at predicting whether a drug would work against a patient’s cancer than simply sequencing a tumor’s DNA. The organoids were 88 percent successful at forecasting whether a patient would respond well to a given drug and were always correct when it came to predicting that a therapy would not be effective, according to results published in the journal Science.
Why it matters: Nicola Valeri, one of the study authors and an investigator at the Institute of Cancer Research in London, says patient-derived organoids can be used to craft ideal individualized treatment plans. He says they would be particularly useful in sorting cancer patients into the right clinical trials, making it more likely that a drug would succeed.
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
How do strong muscles keep your brain healthy?
There’s a robust molecular language being spoken between your muscles and your brain.
The quest to show that biological sex matters in the immune system
A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.